Quantcast
Last updated on April 17, 2014 at 13:22 EDT

Latest Herceptin Stories

2010-06-21 09:25:00

WALTHAM, Mass., June 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019. The Pharmacor 2010 findings from the topic entitled Gastric Cancer reveal that the robust...

2010-04-19 09:23:18

Biopsy MicroRNA that blocks PTEN makes drug less potent against breast cancer WASHINGTON, D.C. - Overexpression of a specific type of microRNA can derail treatment by disabling an important molecular brake on breast cancer cell proliferation, according to evidence presented by researchers from The University of Texas M. D. Anderson Cancer Center at the American Association for Cancer Research 101st Annual Meeting 2010. The study showed that MiRNA-21 interferes with trastuzumab...

2010-03-12 06:30:00

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO) "Halozyme's pipeline programs advanced significantly in 2009 with the...

2010-03-03 13:18:10

A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found. The drugs Herceptin and Tykerb when given together proved to significantly inhibit tumor growth in gastric cancers that had amplified levels of HER2, a mutation that results in an aggressive form of the disease, causing the cancers to...

2009-12-14 22:29:47

Tiny nanoprobes have shown to be effective in delivering cancer drugs more directly to tumor cells "“ mitigating the damage to nearby healthy cells "“ and Purdue University research has shown that the nanoprobes are getting the drugs to right cellular compartments. Professor Joseph Irudayaraj and graduate student Jiji Chen, both in the Department of Agricultural and Biological Engineering, have found that the nanoprobes, or nanorods, when coated with the breast cancer drug...

2009-12-12 12:03:58

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin. Patients using Herceptin and chemotherapy at the same time had a relative 25 percent reduction in the risk of recurrence of cancer or death, compared with women who used Herceptin after chemotherapy, says Edith Perez,...

2009-11-03 09:50:22

Large study finds subset of women that may need additional therapy Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. The findings, published Nov. 2 online in the Journal of Clinical Oncology, is the first large study to...

2009-10-26 15:54:31

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. At issue is how to use a highly effective drug therapy for early-stage breast cancer while maintaining the cardiovascular health of the patient. The drug "“ trastuzumab (herceptin) "“ inhibits...

2009-05-18 12:20:00

ORLANDO, Fla., May 18 /PRNewswire-USNewswire/ -- Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers from the Mayo Clinic campus in Florida report that using a combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as beneficial...

2009-02-11 07:00:00

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai's Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from...